| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Skye Bioscience Inc (PINK: EMBI)
EMBI Technical Analysis
2
| As on 11th Mar 2022 EMBI STOCK Price closed @ 0.04 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.76 & Buy for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EMBISTOCK Price
| Open | 0.04 | Change | Price | % |
| High | 0.04 | 1 Day | 0.00 | 0.00 |
| Low | 0.04 | 1 Week | 0.00 | 0.00 |
| Close | 0.04 | 1 Month | -0.02 | -33.33 |
| Volume | 1004174 | 1 Year | 0.00 | 0.00 |
| 52 Week High 10.14 | 52 Week Low 0.03 | ||||
PINK USA Most Active Stocks
| CYBL | 0.02 | % |
| TXGE | 2920.29 | % |
| SPZI | 0.01 | % |
| AABB | 0.03 | % |
| WRFX | 0.01 | % |
| ICBU | 0.01 | % |
| AMXVF | 1.05 | 10.53% |
| IGPK | 0.01 | % |
| HYSR | 0.02 | % |
| HTZZ | 24.68 | 1.52% |
PINK USA Top Gainers Stocks
PINK USA Top Losers Stocks
| EMBI Daily Charts |
EMBI Intraday Charts |
Whats New @ Bazaartrend |
EMBI Free Analysis |
|
|
EMBI Important Levels Intraday
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
| RESISTANCE | 0.04 |
EMBI Forecast October 2024
| 4th UP Forecast | 0.12 |
| 3rd UP Forecast | 0.09 |
| 2nd UP Forecast | 0.08 |
| 1st UP Forecast | 0.06 |
| 1st DOWN Forecast | 0.02 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | -0.01 |
| 4th DOWN Forecast | -0.04 |
EMBI Weekly Forecast
| 4th UP Forecast | 0.06 |
| 3rd UP Forecast | 0.05 |
| 2nd UP Forecast | 0.05 |
| 1st UP Forecast | 0.05 |
| 1st DOWN Forecast | 0.03 |
| 2nd DOWN Forecast | 0.03 |
| 3rd DOWN Forecast | 0.03 |
| 4th DOWN Forecast | 0.02 |
EMBI Forecast2024
| 4th UP Forecast | 19.54 |
| 3rd UP Forecast | 13.29 |
| 2nd UP Forecast | 9.42 |
| 1st UP Forecast | 5.56 |
| 1st DOWN Forecast | -5.48 |
| 2nd DOWN Forecast | -9.34 |
| 3rd DOWN Forecast | -13.21 |
| 4th DOWN Forecast | -19.46 |
Skye Bioscience Inc ( PINK USA Symbol : EMBI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EMBI Business Profile
Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California. Address: 5910 Pacific Center Boulevard, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service